EDSA — Edesa Biotech, Inc.
Healthcare • Biotechnology
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead...…
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Price
Showing ALL history. Source: FMP historical price full.
- Prev Close
- $1.69
- Day High
- $1.78
- Day Low
- $1.70
- 52w High
- $4.49
- 52w Low
- $1.55
- Volume
- 24,864
- Avg Volume
- Beta
- 0.08
* TTM/most recent where available
Company
- Ticker
- EDSA
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- CA
- CEO
- Pardeep Nijhawan
- Employees
- 16
- Website
- www.edesabiotech.com
Key Metrics
- Market Cap
- 12.4M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).